Systemic Activation of Nrf2 Pathway in Parkinson's Disease
- 1. Unit of Muscular and Neurodegenerative Diseases, Children's Hospital and Research Institute Bambino Gesù I.R.C.C.S., Rome, Italy
- 2. Unit of Muscular and Neurodegenerative Diseases, Children's Hospital and Research Institute Bambino Gesù I.R.C.C.S., and Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- 3. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- 4. IRCCS Fondazione Santa Lucia, and Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Description
Background: Preclinical studies underlined the relevance of Nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor pathway in the pathogenesis of Parkinson’s disease (PD).
Objective: The objective of this study was to explore Nrf2 pathway in vivo in PD, looking for novel disease biomarkers and therapeutic targets.
Methods: The levels of Nrf2, the downstream effectors (NAD(P)H dehydrogenase [quinone] 1 (Nqo1) enzyme, glutathione metabolism enzymes Glutamate–cysteine ligase (GCL) and Glutathione Reductase (GR)), the upstream activators (redox state and mitochondrial dysfunction), and α-synuclein oligomers were assessed in the blood leukocytes of PD patients comparatively to controls. Biochemical data were correlated to clinical parameters.
Results: In PD, Nrf2 was highly transcribed and expressed as well as its target effectors. The mitochondrial complex I activitywas reduced and the oxidized form of glutathione prevailed, disclosing the presence of pathway’s activators. Also, α-synuclein oligomers levels were increased. Nrf2 transcript and oligomers levels correlated with PD duration.
Conclusions: Blood leukocytes mirror pathogenic mechanisms of PD, showing the systemic activation of the Nrf2 pathway and its link with synucleinopathy and clinical events.